GILD
Gilead Sciences, Inc.
Drug Manufacturers - General
Market Cap$169.83B
5Y Perf.+75.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GILD vs REGN
Revenue, margins, valuation, and 5-year total return — side by side.
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$74.89B
5Y Perf.+17.6%
GILD vs REGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GILD | REGN |
|---|---|---|
| Industry | Drug Manufacturers - General | Biotechnology |
| Market Cap | $169.83B | $74.89B |
| Revenue (TTM) | $29.44B | $14.92B |
| Net Income (TTM) | $8.51B | $4.42B |
| Gross Margin | 80.8% | 84.5% |
| Operating Margin | 37.4% | 24.3% |
| Forward P/E | 15.9x | 15.6x |
| Total Debt | $26.71B | $2.71B |
| Cash & Equiv. | $9.99B | $3.12B |
GILD vs REGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GILD
REGN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Gilead Sciences, In… (GILD) | 100 | 175.1 | +75.1% |
| Regeneron Pharmaceu… (REGN) | 100 | 117.6 | +17.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GILD vs REGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GILD leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Regeneron Pharmaceuticals, Inc. is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
GILD
Gilead Sciences, Inc.
The Income Pick
GILD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 10 yrs, beta 0.66, yield 2.3%
- Rev growth 6.0%, EPS growth -91.6%, 3Y rev CAGR 1.7%
- Lower volatility, beta 0.66, current ratio 1.60x
Best for: income & stability and growth exposure
REGN
Regeneron Pharmaceuticals, Inc.
The Long-Run Compounder
REGN is the clearest fit if your priority is long-term compounding.
- 96.0% 10Y total return vs GILD's 92.6%
- Lower P/E (15.6x vs 15.9x)
- 29.6% margin vs GILD's 28.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GILD | 6.0% revenue growth vs REGN's 1.0% |
| Value | REGN | Lower P/E (15.6x vs 15.9x) |
| Quality / Margins | REGN | 29.6% margin vs GILD's 28.9% |
| Stability / Safety | GILD | Beta 0.66 vs REGN's 0.81 |
| Dividends | GILD | 2.3% yield, 10-year raise streak, vs REGN's 0.5% |
| Momentum (1Y) | GILD | +42.5% vs REGN's +29.7% |
| Efficiency (ROA) | GILD | 14.4% ROA vs REGN's 11.1%, ROIC 3.2% vs 8.9% |
GILD vs REGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
GILD vs REGN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGILDLAGGINGREGN
REGNRegeneron Pharmaceuti…
2leads
GILDGilead Sciences, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs REGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
REGN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
GILD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
GILD2/2
Income & Cash Flow (Last 12 Months)
Evenly matched — GILD and REGN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GILD is the larger business by revenue, generating $29.4B annually — 2.0x REGN's $14.9B. Profitability is closely matched — net margins range from 29.6% (REGN) to 28.9% (GILD). On growth, REGN holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $29.4B | $14.9B |
| EBITDAEarnings before interest/tax | $12.4B | $4.2B |
| Net IncomeAfter-tax profit | $8.5B | $4.4B |
| Free Cash FlowCash after capex | $9.7B | $4.2B |
| Gross MarginGross profit ÷ Revenue | +80.8% | +84.5% |
| Operating MarginEBIT ÷ Revenue | +37.4% | +24.3% |
| Net MarginNet income ÷ Revenue | +28.9% | +29.6% |
| FCF MarginFCF ÷ Revenue | +32.8% | +27.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.7% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.5% | -7.2% |
Evenly matched — GILD and REGN each lead in 3 of 6 comparable metrics.
Valuation Metrics
REGN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 17.4x trailing earnings, REGN trades at a 95% valuation discount to GILD's 358.7x P/E. On an enterprise value basis, REGN's 18.1x EV/EBITDA is more attractive than GILD's 42.1x.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $169.8B | $74.9B |
| Enterprise ValueMkt cap + debt − cash | $186.5B | $74.5B |
| Trailing P/EPrice ÷ TTM EPS | 358.68x | 17.38x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.95x | 15.60x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.75x |
| EV / EBITDAEnterprise value multiple | 42.12x | 18.07x |
| Price / SalesMarket cap ÷ Revenue | 5.91x | 5.22x |
| Price / BookPrice ÷ Book value/share | 8.89x | 2.50x |
| Price / FCFMarket cap ÷ FCF | 16.48x | 18.35x |
REGN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
GILD delivers a 37.6% return on equity — every $100 of shareholder capital generates $38 in annual profit, vs $14 for REGN. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to GILD's 1.39x. On the Piotroski fundamental quality scale (0–9), GILD scores 7/9 vs REGN's 5/9, reflecting strong financial health.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +37.6% | +14.3% |
| ROA (TTM)Return on assets | +14.4% | +11.1% |
| ROICReturn on invested capital | +3.2% | +8.9% |
| ROCEReturn on capital employed | +3.4% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | 1.39x | 0.09x |
| Net DebtTotal debt minus cash | $16.7B | -$412M |
| Cash & Equiv.Liquid assets | $10.0B | $3.1B |
| Total DebtShort + long-term debt | $26.7B | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 10.56x | 108.44x |
REGN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
GILD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GILD five years ago would be worth $22,755 today (with dividends reinvested), compared to $14,543 for REGN. Over the past 12 months, GILD leads with a +42.5% total return vs REGN's +29.7%. The 3-year compound annual growth rate (CAGR) favors GILD at 22.8% vs REGN's -1.2% — a key indicator of consistent wealth creation.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +12.8% | -7.0% |
| 1-Year ReturnPast 12 months | +42.5% | +29.7% |
| 3-Year ReturnCumulative with dividends | +85.3% | -3.6% |
| 5-Year ReturnCumulative with dividends | +127.5% | +45.4% |
| 10-Year ReturnCumulative with dividends | +92.6% | +96.0% |
| CAGR (3Y)Annualised 3-year return | +22.8% | -1.2% |
GILD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GILD and REGN each lead in 1 of 2 comparable metrics.
Risk & Volatility
GILD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than REGN's 0.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 0.81x |
| 52-Week HighHighest price in past year | $157.29 | $821.11 |
| 52-Week LowLowest price in past year | $95.30 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +86.7% | +87.8% |
| RSI (14)Momentum oscillator 0–100 | 45.3 | 37.9 |
| Avg Volume (50D)Average daily shares traded | 5.8M | 634K |
Evenly matched — GILD and REGN each lead in 1 of 2 comparable metrics.
Analyst Outlook
GILD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates GILD as "Buy" and REGN as "Buy". Consensus price targets imply 20.1% upside for REGN (target: $866) vs 18.8% for GILD (target: $162). For income investors, GILD offers the higher dividend yield at 2.29% vs REGN's 0.47%.
| Metric | GILDGilead Sciences, … | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $161.88 | $865.68 |
| # AnalystsCovering analysts | 58 | 48 |
| Dividend YieldAnnual dividend ÷ price | +2.3% | +0.5% |
| Dividend StreakConsecutive years of raises | 10 | 1 |
| Dividend / ShareAnnual DPS | $3.12 | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | +5.3% |
GILD leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
REGN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). GILD leads in 2 (Total Returns, Analyst Outlook). 2 tied.
Best OverallGilead Sciences, Inc. (GILD)Leads 2 of 6 categories
Loading custom metrics...
GILD vs REGN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is GILD or REGN a better buy right now?
For growth investors, Gilead Sciences, Inc.
(GILD) is the stronger pick with 6. 0% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 4x trailing P/E (15. 6x forward), making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GILD or REGN?
On trailing P/E, Regeneron Pharmaceuticals, Inc.
(REGN) is the cheapest at 17. 4x versus Gilead Sciences, Inc. at 358. 7x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 15. 6x.
03Which is the better long-term investment — GILD or REGN?
Over the past 5 years, Gilead Sciences, Inc.
(GILD) delivered a total return of +127. 5%, compared to +45. 4% for Regeneron Pharmaceuticals, Inc. (REGN). Over 10 years, the gap is even starker: REGN returned +96. 0% versus GILD's +92. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GILD or REGN?
By beta (market sensitivity over 5 years), Gilead Sciences, Inc.
(GILD) is the lower-risk stock at 0. 66β versus Regeneron Pharmaceuticals, Inc. 's 0. 81β — meaning REGN is approximately 22% more volatile than GILD relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 139% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GILD or REGN?
By revenue growth (latest reported year), Gilead Sciences, Inc.
(GILD) is pulling ahead at 6. 0% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -91. 6% for Gilead Sciences, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GILD or REGN?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus 1. 7% for Gilead Sciences, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus 5. 8% for GILD. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GILD or REGN more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc.
(REGN) trades at 15. 6x forward P/E versus 15. 9x for Gilead Sciences, Inc. — 0. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 20. 1% to $865. 68.
08Which pays a better dividend — GILD or REGN?
All stocks in this comparison pay dividends.
Gilead Sciences, Inc. (GILD) offers the highest yield at 2. 3%, versus 0. 5% for Regeneron Pharmaceuticals, Inc. (REGN).
09Is GILD or REGN better for a retirement portfolio?
For long-horizon retirement investors, Gilead Sciences, Inc.
(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 3% yield). Both have compounded well over 10 years (GILD: +92. 6%, REGN: +96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GILD and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GILD is a mid-cap quality compounder stock; REGN is a mid-cap deep-value stock. GILD pays a dividend while REGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(GILD: 4.7% · REGN: 19.0%)Net Margin>
%
(GILD: 28.9% · REGN: 29.6%)P/E Ratio<
x
(GILD: 358.7x · REGN: 17.4x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.